Fine mapping of human cytotoxic T lymphocyte (CTL) responses against hepatitis C virus (HCV) is based on external loading of target cells with synthetic peptides which are either derived from prediction algorithms or from overlapping peptide libraries. These strategies do not address putative host and viral mechanisms which may alter processing as well as presentation of CTL epitopes. Therefore, the aim of this proof-of-concept study was to identify naturally processed HCV-derived major histocompatibility complex (MHC) class I ligands. To this end, continuous human cell lines were engineered to inducibly express HCV proteins and to constitutively express high levels of functional HLA-A2. These cell lines were recognized in an HLA-A2-restricted manner by HCV-specific CTLs. Ligands eluted from HLA-A2 molecules isolated from large-scale cultures of these cell lines were separated by high performance liquid chromatography and further analyzed by electrospray ionization quadrupole time of flight mass spectrometry (MS)/tandem MS. These analyses allowed the identification of two HLA-A2-restricted epitopes derived from HCV nonstructural proteins (NS) 3 and 5B (NS31406–1415 and NS5B2594–2602). In conclusion, we describe a general strategy that may be useful to investigate HCV pathogenesis and may contribute to the development of preventive and therapeutic vaccines in the future.
References
[1]
Nature Outlook (2011) Hepatitis C. Nature 474: S1–S21.
[2]
Miller FD, Abu-Raddad LJ (2010) Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci U S A 107: 14757–14762.
[3]
Thimme R, Neumann-Haefelin C, B?ttler T, Blum HE (2008) Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine. Biol Chem 389: 457–467.
[4]
Rehermann B (2009) Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 119: 1745–1754.
[5]
Bowen DG, Walker CM (2005) Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436: 946–952.
[6]
Seeff LB (2000) Why is there such difficulty in defining the natural history of hepatitis C? Transfusion 40: 1161–1164.
[7]
Walker CM (2010) Adaptive immunity to the hepatitis C virus. Adv Virus Res 78: 43–86.
[8]
W?lk B, Sansonno D, Kr?usslich HG, Dammacco F, Rice CM, et al. (2000) Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J Virol 74: 2293–2304.
[9]
Schmidt-Mende J, Bieck E, Hügle T, Penin F, Rice CM, et al. (2001) Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem 276: 44052–44063.
[10]
Gremion C, Grabscheid B, W?lk B, Moradpour D, Reichen J, et al. (2004) Cytotoxic T lymphocytes derived from patients with chronic hepatitis C virus infection kill bystander cells via Fas-FasL interaction. J Virol 78: 2152–2157.
[11]
Stickel JS, Stickel N, Hennenlotter J, Klingel K, Stenzl A, et al. (2011) Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation. BMC Urol 11: 1.
[12]
Cerny A, McHutchison JG, Pasquinelli C, Brown ME, Brothers MA, et al. (1995) Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 95: 521–530.
[13]
Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, et al. (2000) Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191: 1499–1512.
[14]
Hillen N, Stevanovic S (2006) Contribution of mass spectrometry-based proteomics to immunology. Expert Rev Proteomics 3: 653–664.
[15]
Crotzer VL, Christian RE, Brooks JM, Shabanowitz J, Settlage RE, et al. (2000) Immunodominance among EBV-derived epitopes restricted by HLA-B27 does not correlate with epitope abundance in EBV-transformed B-lymphoblastoid cell lines. J Immunol 164: 6120–6129.
[16]
Tellam J, Fogg MH, Rist M, Connolly G, Tscharke D, et al. (2007) Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes. J Exp Med 204: 525–532.
[17]
Moradpour D, Kary P, Rice CM, Blum HE (1998) Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins. Hepatology 28: 192–201.
[18]
Brass V, Bieck E, Montserret R, W?lk B, Hellings JA, et al. (2002) An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A. J Biol Chem 277: 8130–8139.
[19]
Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, et al. (2001) Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194: 1395–1406.
[20]
Jo J, Aichele U, Kersting N, Klein R, Aichele P, et al. (2009) Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology 136: 1391–1401.
[21]
Lemmel C, Weik S, Eberle U, Dengjel J, Kratt T, et al. (2004) Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat Biotechnol 22: 450–454.